Invivyd pushes DECLARATION data timeline, names new CEO as PEMGARDA sales rise 18%
Invivyd said Phase 3 data on VYD2311 is now expected imminently after discussions with FDA, as the company reported third-quarter PEMGARDA revenue growth and a leadership change.
SEC filing